<i>MYO5A::FGFR1</i>represents a novel fusion event in pediatric low-grade glioma

Galvin, Robert; Zheng, Cynthia; Fitzpatrick, Garrett; Forster, Colleen L.; Sandoval-Garcia, Carolina; Guillaume, Daniel; Elbermawy, Ahmed; Nelson, Andrew C.; Özütemiz, Can; Chen, Liam; Moertel, Christopher L.

doi:10.1093/noajnl/vdad017

Cited by 1 publication

(1 citation statement)

References 14 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, FGFR1-TACC1 fusions have been reported in extraventricular neurocytoma (EVN) and in cerebral hemispheric PA ( 10 , 13 ). Other fusion events involving FGFR1 ( 37 ) and FGFR2 (e.g. FGFR2-CTNNA3 ) have also been found in polymorphous low grade neuroepithelial tumor of the young (PLNTY ( 13 ).…”

Section: Molecular Landscape Of Plggmentioning

confidence: 99%

Pediatric low-grade glioma models: advances and ongoing challenges

Yvone,

Breunig

2024

Front. Oncol.

View full text Add to dashboard Cite

Pediatric low-grade gliomas represent the most common childhood brain tumor class. While often curable, some tumors fail to respond and even successful treatments can have life-long side effects. Many clinical trials are underway for pediatric low-grade gliomas. However, these trials are expensive and challenging to organize due to the heterogeneity of patients and subtypes. Advances in sequencing technologies are helping to mitigate this by revealing the molecular landscapes of mutations in pediatric low-grade glioma. Functionalizing these mutations in the form of preclinical models is the next step in both understanding the disease mechanisms as well as for testing therapeutics. However, such models are often more difficult to generate due to their less proliferative nature, and the heterogeneity of tumor microenvironments, cell(s)-of-origin, and genetic alterations. In this review, we discuss the molecular and genetic alterations and the various preclinical models generated for the different types of pediatric low-grade gliomas. We examined the different preclinical models for pediatric low-grade gliomas, summarizing the scientific advances made to the field and therapeutic implications. We also discuss the advantages and limitations of the various models. This review highlights the importance of preclinical models for pediatric low-grade gliomas while noting the challenges and future directions of these models to improve therapeutic outcomes of pediatric low-grade gliomas.

show abstract